Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women

B. Lawrence Riggs, W. Michael O'Fallon, Joan Muhs, Michael K. O'Connor, Rajiv Kumar, L. Joseph Melton

Research output: Contribution to journalArticle

231 Citations (Scopus)

Abstract

We report a 4-year randomized, double-blind, placebo-controlled clinical trial in 236 normal postmenopausal women (mean age ± SE, 663 ± 0.2 years) who were randomized to a calcium (1600 mg/day as the citrate) or placebo group. The women were seen every 6 months; 177 completed the trial. Net percentage changes in each group are given relative to baseline. The differences in net percentage changes (calcium group minus placebo group) in medians were: for lumbar spine bone density, 2.0% (p < 0.001) at year 1 and 0.3% (not significant) at year 4; for proximal femur bone density, 1.3% (p = 0.003) at year 1 and 1.3% (p = 0.015) at year 4; and for total body bone mineral, 0.4% (p = 0.002) at year 1 and 0.9% (p = 0.017) at year 4. Similar differences at year 4 were: -18.9% (p = 0.002) for parathyroid hormone (PTH), -11.9% (p = 0.026) for serum osteocalcin, and -32.2% (p = 0.003) for urine free pyridinoline. We conclude that long-term administration of calcium supplements to elderly women partially reverses age-related increases in serum PTH level and bone resorption and decreases bone loss. However, the effects on bone loss were weaker than those reported for estrogen, bisphosphonates, or calcitonin therapy, indicating that calcium supplements alone cannot substitute for these in treating established osteoporosis. Nonetheless, because of their safety, high tolerance, and low expense, calcium supplements may be a useful preventive measure for elderly postmenopausal women whose bone mineral density values are normal for their age.

Original languageEnglish (US)
Pages (from-to)168-174
Number of pages7
JournalJournal of Bone and Mineral Research
Volume13
Issue number2
DOIs
StatePublished - Feb 1998

Fingerprint

Bone Remodeling
Parathyroid Hormone
Calcium
Bone and Bones
Bone Density
Serum
Placebos
Osteocalcin
Controlled Clinical Trials
Diphosphonates
Calcitonin
Bone Resorption
Citric Acid
Femur
Osteoporosis
Minerals
Estrogens
Reference Values
Spine
Urine

ASJC Scopus subject areas

  • Surgery

Cite this

Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. / Riggs, B. Lawrence; O'Fallon, W. Michael; Muhs, Joan; O'Connor, Michael K.; Kumar, Rajiv; Melton, L. Joseph.

In: Journal of Bone and Mineral Research, Vol. 13, No. 2, 02.1998, p. 168-174.

Research output: Contribution to journalArticle

Riggs, B. Lawrence ; O'Fallon, W. Michael ; Muhs, Joan ; O'Connor, Michael K. ; Kumar, Rajiv ; Melton, L. Joseph. / Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. In: Journal of Bone and Mineral Research. 1998 ; Vol. 13, No. 2. pp. 168-174.
@article{10f54ad677724a0ca35642b135ba8fbc,
title = "Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women",
abstract = "We report a 4-year randomized, double-blind, placebo-controlled clinical trial in 236 normal postmenopausal women (mean age ± SE, 663 ± 0.2 years) who were randomized to a calcium (1600 mg/day as the citrate) or placebo group. The women were seen every 6 months; 177 completed the trial. Net percentage changes in each group are given relative to baseline. The differences in net percentage changes (calcium group minus placebo group) in medians were: for lumbar spine bone density, 2.0{\%} (p < 0.001) at year 1 and 0.3{\%} (not significant) at year 4; for proximal femur bone density, 1.3{\%} (p = 0.003) at year 1 and 1.3{\%} (p = 0.015) at year 4; and for total body bone mineral, 0.4{\%} (p = 0.002) at year 1 and 0.9{\%} (p = 0.017) at year 4. Similar differences at year 4 were: -18.9{\%} (p = 0.002) for parathyroid hormone (PTH), -11.9{\%} (p = 0.026) for serum osteocalcin, and -32.2{\%} (p = 0.003) for urine free pyridinoline. We conclude that long-term administration of calcium supplements to elderly women partially reverses age-related increases in serum PTH level and bone resorption and decreases bone loss. However, the effects on bone loss were weaker than those reported for estrogen, bisphosphonates, or calcitonin therapy, indicating that calcium supplements alone cannot substitute for these in treating established osteoporosis. Nonetheless, because of their safety, high tolerance, and low expense, calcium supplements may be a useful preventive measure for elderly postmenopausal women whose bone mineral density values are normal for their age.",
author = "Riggs, {B. Lawrence} and O'Fallon, {W. Michael} and Joan Muhs and O'Connor, {Michael K.} and Rajiv Kumar and Melton, {L. Joseph}",
year = "1998",
month = "2",
doi = "10.1359/jbmr.1998.13.2.168",
language = "English (US)",
volume = "13",
pages = "168--174",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women

AU - Riggs, B. Lawrence

AU - O'Fallon, W. Michael

AU - Muhs, Joan

AU - O'Connor, Michael K.

AU - Kumar, Rajiv

AU - Melton, L. Joseph

PY - 1998/2

Y1 - 1998/2

N2 - We report a 4-year randomized, double-blind, placebo-controlled clinical trial in 236 normal postmenopausal women (mean age ± SE, 663 ± 0.2 years) who were randomized to a calcium (1600 mg/day as the citrate) or placebo group. The women were seen every 6 months; 177 completed the trial. Net percentage changes in each group are given relative to baseline. The differences in net percentage changes (calcium group minus placebo group) in medians were: for lumbar spine bone density, 2.0% (p < 0.001) at year 1 and 0.3% (not significant) at year 4; for proximal femur bone density, 1.3% (p = 0.003) at year 1 and 1.3% (p = 0.015) at year 4; and for total body bone mineral, 0.4% (p = 0.002) at year 1 and 0.9% (p = 0.017) at year 4. Similar differences at year 4 were: -18.9% (p = 0.002) for parathyroid hormone (PTH), -11.9% (p = 0.026) for serum osteocalcin, and -32.2% (p = 0.003) for urine free pyridinoline. We conclude that long-term administration of calcium supplements to elderly women partially reverses age-related increases in serum PTH level and bone resorption and decreases bone loss. However, the effects on bone loss were weaker than those reported for estrogen, bisphosphonates, or calcitonin therapy, indicating that calcium supplements alone cannot substitute for these in treating established osteoporosis. Nonetheless, because of their safety, high tolerance, and low expense, calcium supplements may be a useful preventive measure for elderly postmenopausal women whose bone mineral density values are normal for their age.

AB - We report a 4-year randomized, double-blind, placebo-controlled clinical trial in 236 normal postmenopausal women (mean age ± SE, 663 ± 0.2 years) who were randomized to a calcium (1600 mg/day as the citrate) or placebo group. The women were seen every 6 months; 177 completed the trial. Net percentage changes in each group are given relative to baseline. The differences in net percentage changes (calcium group minus placebo group) in medians were: for lumbar spine bone density, 2.0% (p < 0.001) at year 1 and 0.3% (not significant) at year 4; for proximal femur bone density, 1.3% (p = 0.003) at year 1 and 1.3% (p = 0.015) at year 4; and for total body bone mineral, 0.4% (p = 0.002) at year 1 and 0.9% (p = 0.017) at year 4. Similar differences at year 4 were: -18.9% (p = 0.002) for parathyroid hormone (PTH), -11.9% (p = 0.026) for serum osteocalcin, and -32.2% (p = 0.003) for urine free pyridinoline. We conclude that long-term administration of calcium supplements to elderly women partially reverses age-related increases in serum PTH level and bone resorption and decreases bone loss. However, the effects on bone loss were weaker than those reported for estrogen, bisphosphonates, or calcitonin therapy, indicating that calcium supplements alone cannot substitute for these in treating established osteoporosis. Nonetheless, because of their safety, high tolerance, and low expense, calcium supplements may be a useful preventive measure for elderly postmenopausal women whose bone mineral density values are normal for their age.

UR - http://www.scopus.com/inward/record.url?scp=0031894785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031894785&partnerID=8YFLogxK

U2 - 10.1359/jbmr.1998.13.2.168

DO - 10.1359/jbmr.1998.13.2.168

M3 - Article

C2 - 9495509

AN - SCOPUS:0031894785

VL - 13

SP - 168

EP - 174

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 2

ER -